bioRxiv · 10.1101/729392
Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease
Abstract
Disordered proteins are challenging therapeutic targets, and no drug is currently in clinical use that has been shown to modify the properties of their monomeric states. Here, we identify a small molecule capable of binding and sequestering the amyloid-{beta} peptide (A{beta}) in its monomeric, soluble state. Our analysis reveals that this compound interacts with A{beta} and inhibits both the primary and secondary nucleation pathways in its aggregation process. We characterise this interaction using biophysical experiments and integrative structural ensemble determination methods. We thus observe that this small molecule has the remarkable effect of increasing the conformational entropy of monomeric A{beta} while decreasing its hydrophobic surface area. We then show that this small molecule rescues a Caenorhabditis elegans model of A{beta}-associated toxicity in a manner consistent with the mechanism of action identified from the in silico and in vitro studies. These results provide an illustration of the strategy of targeting the monomeric states of disordered proteins with small molecules to alter their behaviour for therapeutic purposes.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Heller, G. T., Aprile, F. A., Michaels, T. C., Limbocker, R., Perni, M., Ruggeri, F. S., Mannini, B., Lohr, T., Bonomi, M., De Simone, A., Felli, I. C., Pierattelli, R., Knowles, T. P., Dobson, C. M., Vendruscolo, M.. 2019-08-08. Small molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer’s disease. https://doi.org/10.1101/729392
Cite the original work for its findings. Save a collection to share your selection of sources.